Riverwater Partners LLC Buys 8,601 Shares of Delcath Systems, Inc. (NASDAQ:DCTH)

Riverwater Partners LLC raised its position in shares of Delcath Systems, Inc. (NASDAQ:DCTH) by 46.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 27,229 shares of the company’s stock after purchasing an additional 8,601 shares during the period. Riverwater Partners LLC owned 0.09% of Delcath Systems worth $328,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Delcath Systems during the 3rd quarter valued at $102,000. Polar Asset Management Partners Inc. bought a new position in Delcath Systems during the third quarter worth about $1,594,000. State Street Corp increased its stake in shares of Delcath Systems by 12.4% in the third quarter. State Street Corp now owns 85,457 shares of the company’s stock worth $772,000 after purchasing an additional 9,400 shares in the last quarter. Jane Street Group LLC purchased a new position in shares of Delcath Systems in the third quarter worth about $110,000. Finally, Barclays PLC purchased a new stake in shares of Delcath Systems during the 3rd quarter valued at approximately $104,000. 61.12% of the stock is owned by institutional investors.

Delcath Systems Price Performance

Shares of NASDAQ:DCTH opened at $11.01 on Friday. The company has a market cap of $367.77 million, a price-to-earnings ratio of -8.16 and a beta of 0.85. Delcath Systems, Inc. has a one year low of $4.26 and a one year high of $16.97. The firm has a fifty day moving average price of $14.28 and a two-hundred day moving average price of $12.10.

Delcath Systems (NASDAQ:DCTH) last posted its quarterly earnings data on Thursday, March 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.01). Delcath Systems had a negative net margin of 150.70% and a negative return on equity of 338.16%. The business had revenue of $15.10 million for the quarter, compared to the consensus estimate of $14.96 million. During the same period in the prior year, the business posted ($0.48) EPS. Equities research analysts expect that Delcath Systems, Inc. will post -0.79 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently weighed in on DCTH. Craig Hallum lifted their price objective on shares of Delcath Systems from $18.00 to $21.00 and gave the company a “buy” rating in a research note on Friday, January 17th. HC Wainwright lifted their price target on Delcath Systems from $22.00 to $24.00 and gave the company a “buy” rating in a research report on Friday, March 7th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $22.75.

Delcath Systems Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.